TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today that it received the first-place prize for its poster at the The North American Menopause Society (NAMS) 2013 Annual Meeting recently held in Dallas. The poster detailed findings on the first investigational combination 17β-estradiol and progesterone capsule that may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination. TherapeuticsMD is developing this compound, TX 12-001-HR, for FDA review.
Bioavailability of TX 12-001-HR, a capsule containing both 17β-estradiol and progesterone for oral use, was found to be similar to that of the standard reference products for the human hormones estradiol (Estrace ®) and progesterone (Prometrium ®), when taken concurrently. The poster, which was presented by James H. Pickar, M.D., Adjunct Associate Professor of Obstetrics and Gynecology, Columbia University College of Physicians & Surgeons in New York, described findings from a phase 1 study.
"NAMS congratulates TherapeuticsMD on its poster design award. Its poster was selected by an independent poster review committee. NAMS is pleased that so many outstanding research posters on women’s health and menopause were presented at our annual meeting," said Dr. Margery Gass, executive director of The North American Menopause Society.
Posters were evaluated on the basis of five criteria: appropriateness of study design, whether the conclusion flows from the results, overall quality of the science, impact of the study on the field of menopause, and visual appeal of the poster. Each category was rated on a 1-to-5 scale, with 1 = poor, 2 = fair, 3 = satisfactory, 4 = good, and 5 = excellent. The total score for each poster was the sum of the scores given for each of the criteria. Each poster was judged by three experts. The 113 poster presentations evaluated by a judging panel of 23 medical experts were eligible for up to four prizes, with first- and second-place winners receiving cash awards. TherapeuticsMD donated its first-place prize of $1,000 to NAMS.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts